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To ensure the accurate transmission of genetic infor-
mation in dividing cells, specific biochemical pathways
maintain integrity. Fundamental to these pathways is the
recognition, by specific proteins, of genomic lesions,
which signal the presence of DNA damage to other nu-
clear and cytoplasmic factors. DNA strand breaks,
generated either directly by genotoxic agents (oxygen
radicals, ionizing radiations, or monofunctional alky-
lating agents) or indirectly after enzymatic incision of a
DNA-base lesion, trigger the synthesis of poly(ADP-ri-
bose) by the enzyme poly(ADP-ribose) polymerase
(PARP [E.C.2.4.2.30]). PARP is a nuclear zinc-finger
DNA–binding protein that detects DNA strand breaks.
At a breakage site, PARP catalyzes the transfer of the
ADP-ribose moiety, from the respiratory coenzyme
NAD to a limited number of protein acceptors. These
PARP substrates may influence chromatin architecture,
as with histones H1, H2B, and lamin B, or they may
act in DNA metabolism, as with DNA-replication fac-
tors and PARP itself (reviewed by de Murcia and Men-
issier-de Murcia 1994; Oei et al. 1997). Because of the
high negative charge on ADP-ribose polymers (fig. 1A),
poly(ADP-ribosylated) proteins lose their affinity for
DNA and hence, in many cases, their biological activi-
ties. PARP and other modified proteins may be restored
to their native state after poly(ADP-ribose) glycohydro-
lase. Therefore, poly(ADP-ribosylation) is an immediate
posttranslational modification of nuclear DNA–binding
proteins, induced by DNA damaging agents.
The physiological role of PARP has been much de-
bated during this past decade, but molecular and genetic
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approaches have been exploited only recently to study
the role of the immediate poly(ADP-ribose) synthesis
that occurs in response to DNA strand breaks. In this
review, we summarize the most recent findings on PARP,
which define unambiguously its role in cell response to
DNA damage and repair, including cell death by apop-
tosis and some newly reported biological functions for
PARP in different pathologies related to inflammatory
injury to the cell.
PARP and the DNA-Damage Surveillance Network
PARP activity is stimulated 1500-fold on binding to
DNA strand breaks. The human protein spans 1,014
amino acids and comprises three main sequence mod-
ules: an N-terminal DNA-binding domain (DBD) bear-
ing two zinc fingers (FI and FII), which acts as a mo-
lecular nick sensor; a central automodification domain
containing auto-poly(ADP-ribosylation) sites, which
regulate PARP-DNA interactions; and a C-terminal cat-
alytic domain, which performs nick-binding–dependent
poly(ADP-ribose) synthesis (fig. 1; reviewed by de Mur-
cia and Menissier-de Murcia 1994).
Independent experimental approaches have identified
two surfaces on which PARP interacts with its partners
(fig. 1A). Interestingly, in a two-hybrid screen we iden-
tified the base-excision repair (BER) factor XRCC1 (x-
ray cross-complementing-1) as a partner of PARP (Mas-
son et al. 1998). Both proteins interact by their BRCT
(BRCA-1 C-terminus) motifs, andXRCC1 interactswith
DNA ligase III by a second BRCT motif (Caldecott et
al. 1996). This interaction provides strong evidence that
PARP is a member of a BER multiprotein complex that
comprises nick sensors (PARP and DNA ligase III), an
adaptor factor (XRCC1), and the direct mediators of
DNA repair (DNA polymerase b and DNA ligase III).
PARP knockout mice were developed to provide de-
finitive answers about the physiological role of PARP in
different cellular processes. We generated three PARP
knockout mice independently, by disrupting exon 1
(Wang et al. 1997), exon 2 (Menissier-de Murcia et al.
1997), or exon 4 (Masutani et al. 1999) by homologous
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Figure 1 A,Metabolism of poly(ADP-ribose) during DNA dam-
age and repair induced by various genotoxins. B, Domain structure
of human PARP. PARG  poly(ADP-ribose) glycohydrolase; NLS 
nuclear-localization signal. Indicated below the domain structure is the
epitope map of several commonly used antibodies to human PARP.
Shown below are the binding sites of various PARP partners, including
PARP itself, histones, DNA polymerase-a, XRCC1, Oct-1, YY1, and
TEF-1.
recombination. We reported that PARP-deficient mice
are hypersensitive to monofunctional alkylating agents,
such as N-methyl-N-nitrosourea (MNU) and g-rays,
which are potent PARP activators in wild-type (wt) lit-
termates. These results were confirmed in two other con-
structs, at the animal level (Wang et al. 1997) and at the
cellular level (Masutani et al. 1999). As expected, MNU
and g-ray irradiation of mutant mice led to an increase
in reciprocal exchange of DNA segments in sister chro-
matids. These data demonstrate the crucial role of PARP
in the processing of DNA lesions induced by mono-
functional alkylating agents and g-ray irradiation, both
of which trigger the BER pathway.
We evaluated the DNA-repair capacity of PARP-de-
ficient cells, by single-cell electrophoresis, using the
“comet assay,” which monitors the level of broken DNA
in a given cell. After treatment with genotoxins, PARP-
deficient cells display a considerably prolonged delay in
DNA strand–break rejoining, compared with a wt cell
line (Trucco et al. 1998).Whole-cell extracts fromPARP-
deficient cell lines are also defective in the BER path-
way’s polymerization step, which replaces long patches
of basic sites (Dantzer et al., 1999), which is consistent
with evidence that PARP interacts with XRCC1.
PARP and Apoptosis
Apoptosis, or programmed cell death, is a fundamen-
tal biological process that plays an important role in
early development, cell homeostasis, and diseases such
as neurodegenerative disorders and cancer (reviewed by
Evan and Littlewood 1998; also see other reviews in the
same issue of Science). Apoptosis can occur in response
to a number of stimuli, such as genotoxic damage and
withdrawal of growth factors, or after activation of spe-
cific receptors, such as CD95 and the TNF receptor.
Morphologically, this form of cell death is characterized
by membrane blebbing, cell shrinkage, chromatin con-
densation, and DNA cleavage, until finally the cell is
fragmented into membrane-bound apoptotic bodies.
There is increasing biochemical evidence that the caspase
family of cysteine proteases mediates the highly ordered
process leading to cell death. Caspases are responsible
for the disabling of critical homeostatic and repair en-
zymes, as well as of key structural components during
apoptosis. Caspases exist in the cytoplasm as inactive
proenzymes, which are processed to a large and a small
subunit to form the active enzyme (Thornberry and La-
zebnik 1998).
Cleavage of PARP during Apoptosis
Kaufmann et al. (1993) showed that PARP is cleaved
by caspases at a single site at an early stage of apoptosis,
thus separating PARP DBD from its catalytic domain
and inactivating the enzyme. PARP cleavage has been
shown in almost all forms of apoptosis, but, whenever
apoptosis is inhibited by such mechanisms as Bcl-2 over-
expression or caspases inhibition, PARP cleavage is also
blocked (Duriez and Shah 1997). These findings suggest
that loss of PARP function is required for the efficient
completion of apoptosis. To address this model, we ex-
pressed a noncleavable variant of the enzyme in PARP-
deficient cells. Cells that express the PARP mutant
D214A-PARP were exposed to anti-CD95 antibody, a
treatment that induces apoptosis in wt cells, and we
observed a significant delay in cell death (Oliver et al.
1998). Morphological analysis also showed significantly
retarded cell shrinkage and nuclear condensation, indi-
cating that the cleavage of PARP during apoptosis fa-
cilitates cellular disassembly, particularly of the nucleus,
and ensures the completion and irreversibility of this
process.
We propose that caspases cleavage of PARP promotes
apoptosis in two respects: (1) the absence of PARP—and
also of the DNA-dependent protein kinase, another early
target of caspases (Casciola-Rosen et al. 1996)—disables
key aspects of the cellular genomic surveillance mech-
anism and prevents unnecessary DNA repair that would
delay chromatin degradation; and (2) PARP cleavage
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Figure 2 PARP in the network of DNA damage surveillance and
inflammatory cell injury. Under physiological conditions and after lim-
ited damage to DNA, PARP plays a role as a surviving factor allowing
the activation of DNA-repair pathways, through recruitment of the
BER complex. The decision for the cell to engage the apoptotic path-
way after genotoxic damage takes place downstream of p53 activation.
The molecular determinants that switch between DNA repair and cell-
cycle arrest, on one hand, and apoptosis, on the other hand, are not
yet fully understood. Under pathological situations, in which free rad-
icals can damage DNA, PARP activation by massive DNA damage
might deplete NAD cellular stores, altering glycolysis and mitochon-
drial respiration and leading to necrotic-cell death. The failure of the
cell to cleave PARP may contribute to the depletion of cell energy
during necrosis.
improves endonuclease access to chromatin. DNA frag-
mentation during apoptosis is produced by numerous
single-strand nicks in the linker regions of chromatin,
and PARP interacts preferentially with single-stranded
DNA breaks (Le Cam et al. 1994). In this manner, PARP
probably helps recruit BER proteins to repair damaged
DNA. A recent study by Smulson et al. (1998) showed
that the DNA-binding domain of PARP, which is isolated
when it is cleaved by caspase-3, irreversibly binds in-
ternucleosomal DNA in apoptotic cells. This proteolytic
fragment may contribute to the irreversibility of apop-
tosis, by preventing the access of DNA-repair enzymes
to the lesion. The localization of PARP to the nuclear
envelope (Dantzer et al. 1998) also suggests that its
cleavage during apoptosis participates in nuclear disas-
sembly and facilitates downstream events, all of which
are delayed by the expression of the uncleavable PARP
mutant.
The consequences of cleaving several caspase sub-
strates have been probed in a similar manner, by the
expression of uncleavable variants of these target pro-
teins in cells that would otherwise undergo normal apop-
tosis. Sakahira et al. (1998) provided an elegant example
of this approach in their study of caspase-activateddeox-
yribonuclease. Cells expressing an uncleavable variant
of this protein failed to degrade DNA, but they displayed
all the other characteristics of apoptosis. Cells that ex-
press a corresponding mutation in lamin, on the other
hand, showed no signs of chromatin condensation or of
nuclear shrinkage during apoptosis (Rao et al. 1996).
Inhibition of caspase activity causes a switch from a
apoptosis to necrosis (fig. 2; also see also Hirsch et al.
1997), a distinct form of cell death that often arises in
cells deprived of ATP (Leist et al. 1997), as in ischemia.
Induction of apoptosis therefore protects an organism
from necrotic-tissue damage, and the inactivation of
apoptosis may be important in many pathologies. In-
terestingly, PARP is also cleaved during necrosis, al-
though the fragments differ from those found in apop-
totic cells (Gillouf 1999) and retain biological activity
for a longer time. Thus, as depicted in figure 2, the failure
of cells to fully inactivate PARP could lead to massive
NAD consumption and energy depletion, which to-
gether contribute to cell death by necrosis (Szabo and
Dawson 1998).
Apoptosis in PARP-Deficient Cells
DNA damage, such as is caused by treatment of cells
with alkylating agents, activates PARP in normal cells
(Menissier-de Murcia et al. 1997; Oliver et al. 1998) but
also causes PARP/ splenocytes to undergo apoptosis
extremely rapidly (Wang et al. 1997; Oliver et al. 1998).
The extreme sensitivity of PARP/ cells to these agents
could be explained by the accumulation of unrepaired
DNA damage. This view is supported by the observation
that DNA rejoining, as measured by the comet assay, is
prolonged in PARP/ cells (Trucco et al. 1998). In con-
trast to our findings and to those of Wang et al. (1998),
Simbulan-Rosenthal et al. (1998b) reported that PARP-
deficient cells are resistant to cell death after CD95 treat-
ment. This discordant finding would seem to indicate
that PARP activates apoptosis only under some condi-
tions. However, the use, in that study, of immortalized
clones of stably transfected PARP/ embryonic fibro-
blasts—rather than primary cells—may have altered the
cells’ responses to CD95. Overall, the current data sug-
gest that PARP is a passive rather than an active player
in the apoptotic process.
Sensing and Signaling of DNA Damage: PARP and
p53
A number of studies have suggested a role for PARP
and/or poly(ADP-ribose) in p53-mediated DNA dam-
age, although the nature and the consequence of this
interaction are controversial. Some groups have reported
that inhibition or genetic disruption of PARP result in
increased p53 accumulation due to the persistence of
unrepaired DNA. In their pioneering study, Lu and Lane
(1993) found that x-ray–induced p53 accumulation in-
creased in cells treated with the PARP inhibitor, 3-ami-
Oliver et al.: DNA Repair ’99 1285
nobenzamide. Our own results with splenocytes, bone-
marrow cells, and primary embryonic fibroblasts from
PARP-deficient mice show an increased accumulation
of p53 after treatment with an alkylating agent (Men-
issier-de Murcia et al. 1997; F. J. Oliver, G. de la Rubia,
J. Menissier-de Murcia, and G. de Murcia, unpublished
data). A recent report by Simbulan-Rosenthal et al.
(1998a) suggested that inactivation of PARP affects the
duration but not the magnitude of p53 accumulation in
g-ray–irradiated Burkitt lymphoma cells. On the other
hand, other groups have identified PARP as a necessary
step for p53 expression and activation. Whitacre et al.
(1995) suggested that cell lines that were defective in
poly(ADP-ribosylation) had lower basal p53 levels than
were seen in the parental cell line and that they failed
to activate p53 in response to etoposide. Similar results
were obtained with cells cultured in the absence of ni-
cotinamide. A recent report by Wang et al. (1998) sug-
gested that, in some cultured cells, poly(ADP-ribosyla-
tion) is required for rapid accumulation of p53, as well
as for activation of sequence-specific DNA binding and
trans-activation by p53 after DNA damage. Results ob-
tained with PARP/ fibroblasts from one group’s knock-
out mice suggest that the p53 accumulation is controlled
by PARP-dependent and PARP-independent pathways
but that p53 activation is largely independent of PARP
(Agarwal et al. 1997).
It has been proposed that, at themolecular level, PARP
induces p53 induction, either by direct protein-to-pro-
tein interaction or by poly(ADP-ribosylation) (Malanga
et al. 1998). PARP also has been shown to stimulate
DNA-PK activity in vitro by the enzyme’s catalytic sub-
unit, which, in turn, regulates p53 activity by phos-
phorylation (Ruscetti et al. 1998). Indeed, mice deficient
in both PARP and the catalytic subunit of DNA-PK (the
product of the Scid gene; Maizels 1999 [in this issue])
are highly prone to T-cell lymphomas. Neither genetic
deficiency alone is sufficient to cause this phenotype, so
it appears that PARP and DNA-PK cooperate to help
maintain the integrity of the genome (Morrison et al.
1997). Thus, the role of PARP in p53 activation could
be more complex than a direct activation. PARP might
act via DNA-PK and/or other proteins to signal DNA
damage to p53 (fig. 2). The phenotypes of mice with
other combinations of genetic defects, such asATMwith
PARP or P53 with PARP, should clarify the complex
interaction between the different pathways involved in
signaling from DNA damage and transduction to p53.
PARP in Different Pathologies
Studies from several laboratories indicate that PARP
acts in the inflammatory response and in pathologies,
such as brain ischemia, diabetes, and septic shock, that
are associated with inflammatory cell damage. Several
mechanisms have been proposed to explain why inac-
tivation of PARP (either pharmacologically or with ge-
netically engineered animals that lack PARP) improves
the clinical outcome of animals with those conditions.
Szabo and Dawson (1998) recently reviewed the ev-
idence for the following model: either after inflam-
matory stress or during reperfussion after cerebral is-
chemia macrophages and endothelial cells activate a
massive synthesis of nitric oxide (NO), which, in turn,
is converted into a cytotoxic derivative, peroxytrite.
This compound rapidly induces DNA single-strand
breaks, leading to overactivation of PARP in neigh-
boring cells. Depletion of cellular energy then causes
mitochondria to generate free radicals and to kill the
cells by a necrotic mechanism (fig. 2). Results from
our group (F. J. Oliver, J. Menissier-de Murcia, and
G. de Murcia, unpublished data) show a functional
association between PARP and NF-kB, a key regulator
of transcription during inflammation. Through this
association, PARP—and, probably, poly(ADP-ribo-
sylation)—regulate NF-kB–dependent transcription.
Thus, PARP appears to promote inflammation, both
by mediating the cytotoxicity of NO derivatives and
by its affect on NF-kB. One or both of these mecha-
nisms might explain the resistance of PARP/ mice
to brain ischemia, in which synthesis of NO and TNF-
a up-regulation play a crucial role (Barone et al.
1997).
Two very recent reports, by Masutani et al. (1999)
and Burkart (1999), indicate that PARP-mutant mice
enjoy an increased resistance to streptozotocin-induced
diabetes. Interestingly, this autoimmune condition re-
sults in part from inflammatory damage to pancreatic-
islet b-cells. Several studies have also implicated PARP
in systemic lupus erythematosus (SLE), an autoimmune
disorder characterized by production of autoantibodies
against intracellular antigens, including DNA. In one
study, individuals with SLE showed a 70% decrease in
PARP activity (Lee et al. 1994). Moreover, a genetic
susceptibility to SLE has been linked to 1q41-q42, which
contains the PARP gene (Tsao et al. 1997; Moser et al.
1998). However, inheritance of this condition appears
to be complex, and the chromosomal locus implicated
also includes other plausible candidate genes, including
the major-histocompatibility-complex gene.
Future Lines of Investigation
PARP in Transcription and Chromatin Remodeling
Throughout the past several years, PARP has been
shown to interact with a variety of transcription factors
in addition to p53. The transcription factors YY1, AP2
(Oei et al. 1998), OCT1 (Nie et al. 1998), mCAT (Butler
and Ordahl 1999), and DF4 (Plaza et al. 1999) all either
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interact with PARP in vitro or are found to be poly(ADP-
ribosylated). Interestingly, the automodification domain
of PARP, which encompasses a BRCT domain (Leadon
1999 [in this issue]), is responsible for complex for-
mation between PARP and Oct-1 or DF4 (fig. 1). The
BRCT domain of BRCA1 contains the minimal tran-
scriptional activation domain of this protein and regu-
lates p53-dependent gene expression (Ouchi et al. 1998).
In spite of increasing evidence that PARP influences the
transcriptional activation of a number of genes, further
experimental approaches are needed to elucidate themo-
lecular interaction between PARP and the transcription
machinery. In this regard, the propensity of PARP to
bind with DNA crossovers and to induce DNA loops in
undamaged DNA deserves more attention (de Murcia
and Menissier-de Murcia 1994). This property, which
PARP shares with topoisomerases (Zechiedrich andOsh-
eroff 1990), may have important implications for both
the anchoring of chromatin loops to the nuclear matrix
and the loading of transactivators at specific sites.
Poly(ADP ribosylation) of histone H1 may represent a
relative simple means by which the cell destabilizes
higher-order chromatin structures (de Murcia et al.
1986) and improves the access of transcription factors
to regulatory sequences. We postulate that PARP also
ADP ribosylates DNA-bound transcription factors and
modulates their biological activity, as has been shown
for p53 (Malanga et al. 1998). Finally, ADP ribosylation
may also regulate the level of DNA methylation (Zardo
and Caiafa 1998), a well-known marker of promoter
activity.
PARP Homologues
Although for many years it had been assumed that
PARP activity is associated with a single protein, this
assumption has been challenged by the recent discovery
of two PARP homologues: (1) tankyrase, a protein with
regions homologous to ankyrins and to the PARP cat-
alytic domain (Smith et al. 1998), which binds to and
negatively regulates TRF1, a factor involved in telomere
maintenance; and (2) PARP-2, a novel mammalian
DNA-damage–dependent poly(ADP-ribose) polymerase
recently cloned in our laboratory (J. C. Ame´, V. Rolli,
V. Schreiber, Menissier-de Murcia, and G. de Murcia,
unpublished data). The PARP-2 gene maps to chro-
mosomes 14C1 and 14q11.2 in mouse and human, re-
spectively. Although it lacks a classic zinc-finger module,
the recombinant mouse PARP-2 binds to damaged DNA
in vitro and catalyzes the formation of poly(ADP-ribose)
polymers in a DNA-dependent manner. This novel PARP
homologue localizes to the cell nucleus and may serve
as a backup in cell lines that lack the 113-kD PARP
protein. It is clear that more work will be necessary to
unravel the properties of these enzymes and to develop
animal models in which PARP activity is totally
abolished.
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